Unresolved Issues in Antineoplastic Drug Therapy: Is It Finally Time to Address?
August 14th 2023Several articles featured in a recent issue of the highly respected publication the Medical Letter on Drugs and Therapeutics highlight themes across drug development that are relevant within the broad antineoplastic arena. The topics range from appropriate control arms in randomized clinical trials to sponsorship of trials to the rationale for developing novel agents when suitable, cost-effective biosimilar and generic products are available.
Dr Massarelli on Effectively Treating Patients During the United States Chemotherapy Shortage
August 8th 2023Erminia Massarelli MD, PhD, MS, discusses strategies created by City of Hope to effectively navigate the treatment of patients with lung cancer during the platinum chemotherapy shortage in the United States.
Data With Novel Agents Prompt Treatment Sequencing Discussions in MCL and CLL
August 3rd 2023Catherine C. Coombs, MD, and Alexey Danilov, MD, PhD, moderate a discussion on the role and sequencing of BTK inhibitors, venetoclax-based regimens, and CAR T-cell therapy in mantle cell lymphoma and chronic lymphocytic leukemia.
Dr Kim on the Bridging the Gaps in Lung Cancer Meeting
August 3rd 2023Edward S. Kim, MD, MBA, discusses the importance of the Bridging the Gaps in Lung Cancer meeting, and expands on the importance of educating clinicians on how to best implement new developments within lung cancer to address these gaps in care.
Lung Cancer Trials Require Modified Eligibility Criteria to Better Reflect Real-World Population
July 28th 2023Edward S. Kim, MD, MBA, discusses necessary changes that would make cancer research more accessible to patients in community settings, multidisciplinary efforts that should take place at every step of the trial design and implementation process, and how future clinical trials should be intentional about the patient demographics.
Examining the Promise of Multicancer Early Detection Tests: Looking to the Future
July 26th 2023In this seventh episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss the data that are still needed to inform optimal utilization of multicancer early detection tests and their potential cost effectiveness.
Evaluating Toxicities of Antineoplastic Drug Therapeutics: Is It Time for a Critical Review?
July 24th 2023An evaluation of the utility of a cancer therapeutic in a clinical trial is determined through metrics that define 2 distinctive features of an antineoplastic strategy: efficacy and toxicity. Although that may be an oversimplification, the aim of such therapy is to improve clinical outcomes.
Phase 1b Data Support Continued Investigation of Acalabrutinib Plus BR in MCL
July 19th 2023Tycel Phillips, MD, discusses the rationale and design of a phase 1b trial investigating acalabrutinib plus bendamustine and rituximab in patients with mantle cell lymphoma, highlights key efficacy and safety findings in the treatment-naïve and relapsed/refractory patient cohorts, and postulated next steps on the horizon for investigating BTK inhibitors in combination with chemotherapy in this patient population.
Examining the Promise of Multicancer Early Detection Tests: Takeaways From the ECLIPSE Trial
July 19th 2023In this sixth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss important takeaways from the ECLIPSE study (NCT04136002), which evaluated a cell-free DNA blood-based test for colorectal cancer in an average-risk population.
Examining the Promise of Multicancer Early Detection Tests: Lessons Learned From PATHFINDER
July 12th 2023In this fifth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, walk through the key lessons learned from the prospective, multicenter PATHINDER study (NCT04241796), which evaluated a multicancer early detection test developed by GRAIL.
Interpreting Clinical Trial Data Is Not as Simple as It May Seem
July 10th 2023In our fast-moving world where a report of a clinically important trial finding may be simply a 60-second sound bite for both lay and medical communities, it is critical that great care must be taken that reported conclusions are understandable to all, not just the statisticians.
PSCA-Targeted CAR T-Cell Therapy Demonstrates Safety, Anticancer Activity in mCRPC
The use of prostate stem cell antigen–targeted CAR T-cell therapy was well tolerated and produced evidence of anticancer effects in patients with metastatic castration-resistant prostate cancer.
Examining the Promise of Multicancer Early Detection Tests: Existing Concerns
July 5th 2023In this fourth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss existing concerns regarding multicancer early detection tests.
Examining the Promise of Multicancer Early Detection Tests: Need for a Multidisciplinary Clinic
June 28th 2023In this third episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, underscore the need for a multidisciplinary clinic to appropriately interpret multicancer early detection test results.
Examining the Promise of Multicancer Early Detection Tests: Research Efforts Under Way
June 21st 2023In this second episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss some of the challenges faced with randomized control trials and 2 efforts underway that are slated to provide revelatory data on these assays.
Real-World Analysis Supports Use of Brexu-Cel in Relapsed/Refractory MCL
June 15th 2023The real-world efficacy and safety of brexucabtagene autoleucel were similar to the outcomes seen in the phase 2 ZUMA-2 trial, regardless of patients’ treatment history, according to results from a real-world subgroup analysis of patients with relapsed/refractory mantle cell lymphoma.
Examining the Promise of Multicancer Early Detection Tests: Overview and Call for RCTs
June 14th 2023In this first episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, provide an overview on multicancer early detection tests and the need for randomized clinical trials to further explore their use.